What is HemoSonics?
Headquartered in Charlottesville, Virginia, with manufacturing operations in Durham, North Carolina, HemoSonics is a medical device innovator dedicated to enhancing clinical decision-making in critical care settings. The company's flagship technology, the Quantra Hemostasis Analyzer, represents a paradigm shift in how clinicians manage bleeding. By providing rapid, actionable coagulation data, the device facilitates more efficient workflows and improved patient outcomes, effectively reducing the overall economic burden on healthcare systems.
As a key component of the Stago group, HemoSonics benefits from deep industry expertise in thrombosis and hemostasis. This integration allows the company to combine its proprietary diagnostic technology with a robust global distribution network, ensuring that its point-of-care solutions reach the clinical environments where they are most needed to save lives and optimize resource allocation.
How much funding has HemoSonics raised?
HemoSonics has raised a total of $25.9M across 6 funding rounds:
Unspecified
$1M
Unspecified
$1.3M
Private Equity
$3.7M
Private Equity
$4M
Private Equity
$15M
Debt
$1M
Unspecified (2008): $1M, investors not publicly disclosed
Unspecified (2013): $1.3M, investors not publicly disclosed
Private Equity (2014): $3.7M, investors not publicly disclosed
Private Equity (2015): $4M, investors not publicly disclosed
Private Equity (2017): $15M, investors not publicly disclosed
Debt (2020): $1M with participation from PPP
Key Investors in HemoSonics
PPP
Public-Private Partnership
Undisclosed Investor
An institutional backer involved in previous private equity rounds, supporting the company's transition to commercial-scale manufacturing.
Undisclosed Investor
A strategic partner contributing to the long-term development of the Quantra Hemostasis Analyzer and associated clinical diagnostic infrastructure.
What's next for HemoSonics?
With the recent capital deployment, HemoSonics is well-positioned to accelerate the adoption of the Quantra platform across international markets. The strategic focus will likely center on expanding the clinical utility of its diagnostic tools, potentially through new software integrations or expanded regulatory clearances for diverse patient populations. As the healthcare industry continues to prioritize value-based care, HemoSonics' ability to deliver precise, real-time data will remain a critical competitive advantage.
Furthermore, the ongoing synergy with the Stago group suggests a roadmap focused on scaling manufacturing capabilities and deepening research into complex coagulation disorders. By maintaining a rigorous focus on clinical efficacy and operational efficiency, HemoSonics is poised to define the next generation of point-of-care diagnostics, ensuring that its technology remains at the forefront of modern medical practice.
